Abstract
Researchers are closer to understanding the role of aspirin and NSAIDs in preventing colorectal cancer, according to the findings from several studies presented at Digestive Disease Week [ San Diego, US; May 1995 ]. New analyses of data from the Polyp Prevention Study 1 (PPS 1) confirm that aspirin use reduces the recurrence of large bowel adenomas. However, the dosage of aspirin that may achieve this effect remains unknown. On a mechanistic note, data from in vitro studies and a study in patients with familial adenomatous polyposis (FAP) indicate that sulindac may cause adenoma regression by inducing apoptosis. In addition, the novel NSAID balsalazide, a prodrug of 5-aminosalicylic acid, has been shown to inhibit human cancer cell proliferation in vitro.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
